Pfizer Advances Once-Daily Oral GLP-1 Weight Loss Drug Danuglipron

Gelonghui July 11 | Pfizer (PFE.US): Advancing the development of Danuglipron, a once-daily oral GLP-1 weight loss medication. Studies show that Danuglipron has favorable pharmacokinetic properties. Dose optimization studies are planned for the second half of 2024.